Pharos iBio Co., Ltd.

As of June 30, 2026, Pharos iBio Co., Ltd. carries a market capitalization of 68.74B, placing it among publicly traded companies globally. Its enterprise value stands at 55.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Pharos iBio Co., Ltd. has 12.95M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Pharos iBio Co., Ltd. maintains a current ratio of 28.33, meaning it holds 28.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.24, indicating elevated leverage, while an interest coverage ratio of -10.48 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharos iBio Co., Ltd. posted a negative return on equity (ROE) of -83.69, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -47.42, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Pharos iBio Co., Ltd.'s stock has gained approximately 12.45% over the past 52 weeks. The 50-day moving average sits at 5,682.20, while the 200-day moving average is 7,429.83.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -9.72B, while operating income came in at -10.58B.

As of June 30, 2026, Pharos iBio Co., Ltd. holds 22.30B in cash and equivalents against 8.87B in total debt, resulting in a net debt position of 3.16B. Total book value stands at 9.72B, with working capital of 22.33B providing operational flexibility.

Pharos iBio Co., Ltd. produced -6.58B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -405.87M in capital expenditures, free cash flow totaled -6.98B - equivalent to -539.03 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -27.25, meaning Pharos iBio Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.